METMET
US • —
$84.61
P/E
15.53
PEG
—
FCF Yield
—
Rev Growth YoY
+5.3% YoY
Gross Margin
—
Health Score
6/10
D/E Ratio
0.67
Confidence
LOW
Business Snapshot
This company operates in a sector that has attracted moderate valuation interest from investors, given a current P/E ratio below the broader sector benchmark. With a price-to-sales ratio of 0.7x and price-to-book of 1.83x, the market appears to be pricing the business conservatively relative to its balance sheet. The company maintains a debt-to-equity ratio of 0.67x and a return on equity of 12.9%, indicating it can generate profits from shareholder capital without excessive leverage. A notable characteristic is the high analyst conviction, with 70% of covering analysts issuing Buy ratings, suggesting a degree of institutional confidence in the company's prospects.
Financial Health
The company's net margin of 4.7% provides a baseline level of profitability but does not indicate a wide competitive moat tied to operational efficiency. The balance sheet appears manageable with a debt-to-equity ratio of 0.67x, though the current ratio of 0.19x is extremely low, pointing to significant short-term liquidity risk and potential difficulty covering near-term obligations without refinancing or asset sales...
Risk Assessment
- LIQUIDITY — Current ratio of 0.19x is critically low, indicating the company has very limited current assets relative to short-term liabilities, creating potential distress risk.
- EARNINGS QUALITY — Earnings declined by 15.2% year-over-year, significantly underperforming the modest 5.3% revenue growth, suggesting margin pressure or cost structure issues.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- VALUATION DIVERGENCE — DCF estimates are not calculable due to negative or unavailable free cash flow, preventing a fundamental check on whether the current P/E discount is justified.
- DATA COMPLETENESS — One core fundamental metric is missing from the payload, limiting the depth of fundamental analysis and introducing uncertainty....
The company's net margin of 4.7% provides a baseline level of profitability but does not indicate a wide competitive moat tied to operational efficiency. The balance sheet appears manageable with a debt-to-equity ratio of 0.67x, though the current ratio of 0.19x is extremely low, pointing to significant short-term liquidity risk and potential difficulty covering near-term obligations without refinancing or asset sales. Free cash flow data is not available for this period, making it impossible to assess the company's cash generation or its ability to self-fund operations. A return on equity of 12.9% suggests the company is generating reasonable returns on shareholder equity, but the combination of low current assets and unavailable FCF data creates an incomplete picture of financial health. Overall, the company shows mixed financial health — reasonable leverage and profitability, but a concerning liquidity position that would limit dividend capacity and raise questions about reinvestment flexibility.
- LIQUIDITY — Current ratio of 0.19x is critically low, indicating the company has very limited current assets relative to short-term liabilities, creating potential distress risk. - EARNINGS QUALITY — Earnings declined by 15.2% year-over-year, significantly underperforming the modest 5.3% revenue growth, suggesting margin pressure or cost structure issues. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - VALUATION DIVERGENCE — DCF estimates are not calculable due to negative or unavailable free cash flow, preventing a fundamental check on whether the current P/E discount is justified. - DATA COMPLETENESS — One core fundamental metric is missing from the payload, limiting the depth of fundamental analysis and introducing uncertainty.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives